Details der Publikation - Long term continuous infusion ch14.18/CHO plus s.c. aldesleukin (IL-2) randomised

Long term continuous infusion ch14.18/CHO plus s.c. aldesleukin (IL-2) randomised : A PHASE I/II DOSE SCHEDULE FINDING STUDYFOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2)IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA - Long term continuous infusion ch14.18/CHO

Medienart:	Klinische Studie

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	WHO International Clinical Trials Registry Platform - (2023) vom: 21. Juni Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: High-risk neuroblastoma patients having received at least one previous high dose treatment followed by stem cell rescue after conventional therapy fulfilling one of the following criteria:•Primary refractory patients with stage 4 disease with at least two lines of treatment prior to HDT/SCT, causing a delay from diagnosis to SCT of over 9 months •Relapse after primary stage 4 disease•Disseminated relapse after primary localized neuroblastoma;Therapeutic area: Diseases [C] - Cancer [C04] Phase: Phase 1 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 24-09-2010, Last updated: 2023-06-29

ICTRP ID:	EUCTR2009-018077-31-AT 012010

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG004698886

Internformat


LEADER	01000caa a22002652 4500
001	CTG004698886
003	DE-627
005	20230629100628.0
007	cr uuu---uuuuu
008	210507s2023 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)CTG004698886
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2009-018077-31-AT
035			\|a (UBBS_Klinische_Studien_WHO)012010
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Long term continuous infusion ch14.18/CHO plus s.c. aldesleukin (IL-2) randomised \|b A PHASE I/II DOSE SCHEDULE FINDING STUDYFOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2)IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA - Long term continuous infusion ch14.18/CHO
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 24-09-2010, Last updated: 2023-06-29
650		4	\|a Medical Condition: High-risk neuroblastoma patients having received at least one previous high dose treatment followed by stem cell rescue after conventional therapy fulfilling one of the following criteria:•Primary refractory patients with stage 4 disease with at least two lines of treatment prior to HDT/SCT, causing a delay from diagnosis to SCT of over 9 months •Relapse after primary stage 4 disease•Disseminated relapse after primary localized neuroblastoma;Therapeutic area: Diseases [C] - Cancer [C04]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 1
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2023) vom: 21. Juni
773	1	8	\|g year:2023 \|g day:21 \|g month:06
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-018077-31 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
951			\|a AR
952			\|j 2023 \|b 21 \|c 06

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände